Genomic analyses of non-small cell lung cancer (NSCLC) have revealed precision medicine targets, e.g., mutated epidermal growth factor receptor (EGFR) and ALK fusions [1,2,3]. Here, ALK is linked to non-small cell lung carcinoma.